Collects tumor samples to study cancer differences in minority patients
Collects tumor samples from people with bladder, stomach, liver, or lung cancer.
Plain-language title generated from the registry record
Registry title: Patient-Derived Xenografts to Reduce Cancer Health Disparities
Key facts
- Where
- Orange and Sacramento, United StatesSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults being treated for bladder, lung, stomach or liver cancer. Tumour samples are used to grow cancer models in the lab.
- Age
- 21 to 100 years
- Sex
- All sexes can join.
- Disease stage
- Bladder cancer, lung cancer, gastric (stomach) cancer or liver cancer. No stage is named.
Main reasons for not taking part
- No signed informed consent
- Specimen unacceptable or degraded
- People who are not yet adults
- Pregnant women
- Prisoners
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 100 years old?
Source: NCT04410302, who can take part
Where in United States
- UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, United StatesTaking people
- University of California Davis Comprehensive Cancer CenterSacramento, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, Davis
- Trial code
- NCT04410302
- Record updated
- 20 August 2026
- Original description
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.Read full original descriptionShow less
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Inclusion: Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer); Signed informed consent that will be put on file.
Exclusion: No informed consent obtained; Specimen unacceptable/degraded/etc; Individuals who are not yet adults (infants, children, teenagers); Pregnant women; Prisoners; Adults unable to consent.